Tolvaptan
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Hypervolemic hyponatremia (serum Na <125 mEq/L, or symptomatic and refractory to fluid restriction) | Adults (including heart failure) | Monotherapy or adjunct to fluid restriction | FDA Approved |
| Euvolemic hyponatremia (serum Na <125 mEq/L, or symptomatic and refractory to fluid restriction) | Adults (including SIADH) | Monotherapy or adjunct to fluid restriction | FDA Approved |
| Autosomal dominant polycystic kidney disease (ADPKD) — to slow kidney function decline in at-risk patients | Adults (via Jynarque, under REMS) | Chronic disease-modifying therapy | FDA Approved |
Tolvaptan is used primarily in the hospital setting for the correction of clinically significant hyponatremia that has not responded to fluid restriction. The drug is not intended for patients who require urgent sodium correction to prevent serious neurological injury, as its onset is gradual (2–4 hours). The ADPKD indication is managed exclusively through the Jynarque REMS program due to hepatotoxicity risk with chronic dosing. This monograph focuses primarily on the Samsca (hyponatremia) indication.
Acute decompensated heart failure with congestion (evidence: moderate) — The EVEREST trial evaluated tolvaptan 30 mg daily as adjunctive therapy in HF patients. While it improved short-term congestion markers, it did not reduce mortality or HF hospitalization. Some clinicians use it for volume management in diuretic-resistant HF.
Hyponatremia in cirrhosis (evidence: moderate) — Tolvaptan raised serum sodium in the cirrhotic subset of the SALT trials; however, gastrointestinal bleeding occurred at a higher rate (10% vs 2% placebo) in cirrhotic patients, warranting caution. The 30-day treatment cap is especially relevant in this population due to hepatotoxicity risk.
Dosing
Hyponatremia — Adult Inpatient Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Euvolemic hyponatremia (SIADH) — initial correction | 15 mg once daily | 15–60 mg once daily | 60 mg/day | Must initiate in hospital. Titrate at ≥24 h intervals based on serum Na response Avoid fluid restriction during first 24 h to prevent overly rapid correction |
| Hypervolemic hyponatremia (heart failure) — adjunct to standard therapy | 15 mg once daily | 15–60 mg once daily | 60 mg/day | No additional dose adjustment for HF beyond standard titration Monitor for hyperkalemia when combined with ACEi/ARB/spironolactone |
| Hyponatremia in cirrhosis — short-term use | 15 mg once daily | 15–60 mg once daily | 60 mg/day | Higher GI bleeding risk in cirrhotics (10% vs 2%) Limit to 30 days; avoid in underlying liver disease (FDA PI) |
| Renal impairment (CrCl 10–79 mL/min) | 15 mg once daily | Standard titration | 60 mg/day | No dose adjustment needed. Onset/offset of Na effect may be slower in severe impairment Not recommended if CrCl <10 mL/min or anuric (no benefit expected) |
| Concomitant moderate CYP3A4 inhibitor | Avoid concomitant use | If unavoidable, consider reduced tolvaptan dose with intensified sodium monitoring Strong CYP3A4 inhibitors are contraindicated (5-fold AUC increase) | ||
Target correction should not exceed 10–12 mEq/L in the first 24 hours. In the SALT trials, 7% of tolvaptan-treated patients with baseline Na <130 mEq/L had a rise >8 mEq/L at 8 hours, and 2% exceeded 12 mEq/L at 24 hours. Patients with SIADH or very low baseline sodium are at greatest risk. If overcorrection occurs, discontinue tolvaptan and consider administration of hypotonic fluid. Desmopressin is typically ineffective during V2 receptor blockade.
Do not administer tolvaptan for longer than 30 days to minimize the risk of hepatic injury (FDA PI). Following discontinuation, advise patients to resume fluid restriction and monitor serum sodium, as levels typically decline within 7 days of stopping therapy.
Pharmacology
Mechanism of Action
Tolvaptan is a selective, competitive antagonist of the vasopressin V2 receptor, binding with approximately 1.8 times the affinity of native arginine vasopressin (AVP) and 29-fold selectivity over the V1a receptor. By blocking V2 receptors in the renal collecting duct principal cells, tolvaptan prevents AVP-mediated insertion of aquaporin-2 water channels into the apical membrane. This inhibits free water reabsorption from the collecting duct lumen, producing aquaresis — the selective excretion of electrolyte-free water without meaningful changes in urinary sodium or potassium excretion. The resulting decrease in body water raises serum sodium concentration and reduces plasma osmolality toward normal. Tolvaptan metabolites have negligible V2 receptor activity. The aquaretic effect begins within 2–4 hours of oral dosing, peaks between 4–8 hours, and approximately 60% of the peak sodium-raising effect persists at 24 hours. Doses above 60 mg do not produce additional aquaresis.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Bioavailability 56% (30 mg dose; range 42–80%); Tmax 2–4 h; high-fat meal doubles Cmax but does not change AUC | Can be taken with or without food; rapid onset allows same-day titration assessment |
| Distribution | Vd ~3 L/kg; >98% protein bound (albumin and α1-acid glycoprotein); binding unaffected by disease | Wide tissue distribution; dialysis is ineffective for removal due to high protein binding |
| Metabolism | Almost exclusively by CYP3A4; 14 metabolites identified; major circulating metabolite is oxobutyric acid (t½ ~180 h); no pharmacologically active metabolites | Highly vulnerable to CYP3A4 inhibitors (ketoconazole: 5.4-fold AUC increase) and inducers (rifampin: 85% AUC decrease) |
| Elimination | 40% urine (<1% unchanged), 59% feces (19% unchanged); terminal t½ ~12 h (oral, dose-dependent; IV t½ ~3 h); apparent CL ~4 mL/min/kg | Primarily non-renal elimination; no dose adjustment for renal impairment above CrCl 10 mL/min |
Side Effects
Adverse reaction data below are from the two 30-day, double-blind, placebo-controlled SALT hyponatremia trials (N = 223 tolvaptan, N = 220 placebo), with supplementary data from the EVEREST heart failure trial where noted (FDA PI).
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Thirst / polydipsia | 16% vs 5% placebo | Pharmacologically predictable aquaretic effect; patients should drink freely in response to thirst |
| Dry mouth | 13% vs 4% placebo | Related to aquaresis; usually mild and self-limiting |
| Pollakiuria / polyuria | 11% vs 3% placebo | Direct consequence of V2 blockade; nocturia may occur and affect adherence |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Asthenia | 9% vs 4% placebo | May be related to fluid shifts; monitor hydration status |
| Constipation | 7% vs 2% placebo | Likely related to decreased gastrointestinal water content from aquaresis |
| Hyperglycemia | 6% vs 1% placebo | Monitor blood glucose in diabetic patients; mechanism not fully characterized |
| Anorexia / decreased appetite | 4% vs 1% placebo | Mild; may overlap with symptoms of underlying disease (HF, cirrhosis) |
| Pyrexia | 4% vs 1% placebo | Not clearly dose-related; rule out infection in hospitalized patients |
| Dehydration | 3.3% vs 1.5% placebo | Risk is higher in volume-depleted patients and with concomitant diuretics |
| Nausea (HF population) | ~5% excess vs placebo | 21% tolvaptan vs 16% placebo in EVEREST hyponatremic subgroup (9-month data) |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Osmotic demyelination syndrome (ODS) | Rare | Days to weeks after overly rapid Na correction | Discontinue tolvaptan immediately; administer hypotonic fluid; neurological assessment; ICU-level monitoring |
| Hepatotoxicity (with chronic use for ADPKD) | Uncommon (Hy’s Law cases in ADPKD trials) | Typically first 18 months of chronic therapy | Discontinue permanently; liver function testing; for Samsca, limit use to 30 days |
| Hypernatremia | 1.7% (vs 0.8% placebo by lab values) | Any time during treatment | Reduce dose or interrupt therapy; modify free-water intake; monitor electrolytes |
| Gastrointestinal bleeding (cirrhotic patients) | 10% (vs 2% placebo in cirrhotic subgroup) | Variable | Monitor for signs of bleeding; withhold therapy; endoscopy as indicated |
| Anaphylaxis / severe hypersensitivity | Very rare (postmarketing) | Any time | Emergency care; permanent discontinuation; do not rechallenge |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Aquaretic effects (thirst, polyuria, pollakiuria) | ~2–3% | Short-term hyponatremia trials; up to 6.6% in chronic ADPKD use |
| Hepatic adverse events | <1% | Primarily a concern with chronic ADPKD dosing; rare within 30-day hyponatremia use |
| Death (all causes) | 6% (both groups) | Reflects underlying disease severity (HF, cirrhosis); no excess mortality with tolvaptan |
Thirst and polyuria are pharmacologically expected effects and the most common reasons patients find tolvaptan difficult to tolerate long-term. Counsel patients that they should drink water freely whenever thirsty. Fluid restriction during the first 24 hours of therapy is specifically contraindicated because it increases the risk of overly rapid sodium correction. After the first 24 hours, fluid restriction may be cautiously resumed if clinically indicated, but patients should always maintain ad-libitum access to water.
Drug Interactions
Tolvaptan is metabolized almost exclusively by CYP3A4 and is also a substrate and inhibitor of P-glycoprotein (P-gp) and BCRP. Its major circulating metabolite (oxobutyric acid) inhibits OATP1B1 and OAT3. The CYP3A4 dependency creates the most clinically significant interaction pathway.
Monitoring
-
Serum Sodium
At 8 h post-first dose, then daily for 48–72 h, then at titration, then days 11, 18, 25, 30
Routine Critically important to detect overly rapid correction. If Na rises >12 mEq/L in 24 h, discontinue tolvaptan and administer hypotonic fluid. Also check 7 days after discontinuation as Na typically declines. -
Fluid Balance
Daily during inpatient initiation
Routine Monitor intake, output, and body weight. Dehydration and hypovolemia are risks, especially with concomitant diuretics. Ensure free access to water. -
Serum Potassium
Baseline; during treatment if K >5 mEq/L or on RAAS inhibitors
Trigger-based Volume contraction can concentrate serum potassium. Risk is 1–2% higher when combined with ACEi, ARBs, or potassium-sparing diuretics. -
Liver Function
If symptoms arise (fatigue, anorexia, dark urine, jaundice)
Trigger-based For short-term Samsca use (≤30 days), routine LFT monitoring is not mandated but clinical vigilance is essential. For chronic Jynarque use (ADPKD), monthly LFTs are required under the REMS protocol. -
Blood Glucose
Baseline; periodically in diabetic patients
Trigger-based Hyperglycemia was reported in 6% of tolvaptan-treated patients vs 1% placebo. Monitor more frequently in patients with diabetes. -
Neurological Status
During initiation and after each dose titration
Routine Assess for signs of osmotic demyelination: dysarthria, mutism, dysphagia, lethargy, behavioural changes, or new motor deficits. Patients with severe malnutrition, alcoholism, or advanced liver disease are at highest risk.
Contraindications & Cautions
Absolute Contraindications
- Inability to sense or respond to thirst — patients who cannot auto-regulate fluid balance face substantially elevated risk of hypernatremia, dehydration, and overly rapid sodium correction.
- Hypovolemic hyponatremia — aquaresis would worsen volume depletion; tolvaptan is only indicated for euvolemic or hypervolemic states.
- Concomitant strong CYP3A4 inhibitors — ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir, saquinavir, nefazodone, and telithromycin (5-fold exposure increase).
- Anuria — tolvaptan requires functioning renal collecting ducts; no benefit expected in anuric patients.
- Hypersensitivity to tolvaptan or excipients — anaphylactic shock and generalized rash reported in postmarketing.
- ADPKD treatment outside FDA-approved REMS — due to risk of serious hepatotoxicity with chronic dosing.
Relative Contraindications (Specialist Input Recommended)
- Underlying liver disease including cirrhosis — while not absolutely contraindicated, the FDA PI recommends avoiding use due to impaired ability to recover from tolvaptan-associated liver injury, and higher GI bleeding rates observed in cirrhotic patients.
- Very low baseline sodium (<120 mEq/L) — correction rate is less predictable and risk of osmotic demyelination is significantly increased; consider expert consultation before initiation.
- Concomitant hypertonic saline — combination is not recommended as it compounds the risk of overcorrection.
- Severe renal impairment (CrCl <10 mL/min) — no trial data available and drug effects on serum sodium are likely lost; use is not recommended.
Use with Caution
- Concurrent diuretic therapy — increases risk of dehydration, hypovolemia, and overly rapid sodium correction; requires close electrolyte monitoring.
- Patients with serum potassium >5 mEq/L — tolvaptan-induced volume contraction may further elevate potassium.
- Prostatic hypertrophy or urinary outflow obstruction — increased urine production raises risk of acute urinary retention; ensure urinary output is secured before initiating.
- Pregnancy — animal studies showed teratogenicity in rabbits at maternal toxic doses (~1.6x human exposure); insufficient human data; potential risk to fetus.
- Severe malnutrition or chronic alcoholism — heightened susceptibility to osmotic demyelination even with standard correction rates; slower targets may be advisable.
(A) Initiate and re-initiate in a hospital and monitor serum sodium. Tolvaptan must be started in a hospital where serum sodium can be closely monitored. Overly rapid correction of hyponatremia (e.g., >12 mEq/L/24 hours) can cause osmotic demyelination syndrome, resulting in dysarthria, mutism, dysphagia, lethargy, affective changes, spastic quadriparesis, seizures, coma, and death. In susceptible patients (malnutrition, alcoholism, advanced liver disease), slower correction rates may be advisable.
(B) Not for use in ADPKD outside of the FDA-approved REMS. Tolvaptan can cause serious and potentially fatal hepatic injury when used chronically for ADPKD. Liver failure requiring transplantation has been reported in postmarketing experience. For the Samsca indication, therapy duration is limited to 30 days.
Patient Counselling
Purpose of Therapy
Tolvaptan helps raise dangerously low sodium levels in the blood by causing the kidneys to excrete excess water while retaining electrolytes. Treatment is started in the hospital so that sodium levels can be closely monitored, and it is typically used for a limited period (up to 30 days).
How to Take
Take tolvaptan once daily, with or without food, at approximately the same time each day. Do not drink grapefruit juice during treatment. If a dose is missed, take it as soon as remembered unless it is close to the next scheduled dose; never double up. After stopping tolvaptan, follow any fluid restriction advice from the medical team, as sodium levels may decrease again within about a week.
Sources
- SAMSCA (tolvaptan) tablets — Full Prescribing Information. Otsuka America Pharmaceutical, Inc. Revised 04/2021. FDA Label Primary source for all dosing, contraindications, adverse reactions, PK data, and boxed warning language for the hyponatremia indication.
- JYNARQUE (tolvaptan) tablets — Full Prescribing Information. Otsuka Pharmaceutical Development & Commercialization. Revised 2018. FDA Label Source for ADPKD-specific dosing, REMS requirements, and long-term hepatotoxicity data including TEMPO 3:4 adverse events.
- Tolvaptan tablets (generic) — DailyMed Labeling. U.S. National Library of Medicine. DailyMed Confirms availability of generic tolvaptan formulations and provides current labeling for non-branded products.
- Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355(20):2099–2112. doi:10.1056/NEJMoa065181 SALT-1 and SALT-2 pivotal trials establishing tolvaptan’s efficacy in raising serum sodium in euvolemic and hypervolemic hyponatremia across diverse aetiologies.
- Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297(12):1319–1331. doi:10.1001/jama.297.12.1319 Large outcomes trial (N=4133) in HF showing no long-term mortality or morbidity benefit, establishing the safety profile for long-term use and confirming short-term symptom improvement.
- Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297(12):1332–1343. doi:10.1001/jama.297.12.1332 Companion trial to the EVEREST outcome study detailing short-term clinical improvements in body weight, dyspnoea, and oedema.
- Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407–2418. doi:10.1056/NEJMoa1205511 TEMPO 3:4 trial demonstrating that tolvaptan slowed kidney volume growth (2.8% vs 5.5%/year) and functional decline in ADPKD over 3 years, leading to the Jynarque approval.
- Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol. 2010;21(4):705–712. doi:10.1681/ASN.2009080857 SALTWATER open-label extension study (mean 701 days) providing long-term safety and efficacy data for tolvaptan in chronic hyponatremia.
- Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(10 Suppl 1):S1–S42. doi:10.1016/j.amjmed.2013.07.006 US expert panel guidelines positioning vaptans as second-line therapy after fluid restriction for chronic SIADH-related hyponatremia, with dosing and monitoring recommendations.
- Yamamura Y, Ogawa H, Chihara T, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287(3):860–866. PMID:9864265 Original preclinical characterization of tolvaptan (OPC-41061) establishing V2 selectivity, oral bioavailability, and aquaretic dose-response relationships in animal models.
- Shoaf SE, Bricmont P, Mallikaarjun S. Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects. Int J Clin Pharmacol Ther. 2012;50(2):150–156. doi:10.5414/CP201649 Definitive bioavailability study establishing tolvaptan’s absolute oral bioavailability of 56% (at 30 mg) and minimum effective plasma concentration of 20–30 ng/mL.
- Shoaf SE, Bricmont P, Mallikaarjun S. Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function. Kidney Int. 2014;85(4):953–961. doi:10.1038/ki.2013.350 PK study across renal function groups showing higher tolvaptan exposure with declining CrCl but no dose adjustment needed above CrCl 10 mL/min.
- Kim SR, Hasunuma T, Sato O, et al. Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers. Cardiovasc Drugs Ther. 2011;25(Suppl 1):S5–S17. doi:10.1007/s10557-011-6299-3 Single and multiple dose PK characterization confirming dose-dependent half-life prolongation, linear PK up to 60 mg, and racial consistency of PK parameters.
- Shoaf SE, Mallikaarjun S, Bricmont P. Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis. Br J Clin Pharmacol. 2013;76(3):432–447. doi:10.1111/bcp.12053 Population PK modelling demonstrating reduced clearance in HF (45–58% of healthy) and cirrhosis (58%), informing special population dosing considerations.